Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 1.93 per share.
For the full year, analysts predict revenues of $ 311.93 million, while looking forward to loss of $ 8.47 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 300.00 million ~ $ 320.00 million
Click Here For More Historical Outlooks Of Intercept Pharmaceuticals, Inc.
Previous Quarter Performance
Intercept Pharmaceuticals, Inc. communicated loss for the second quarter of $ 1.92 per share, from the revenue of $ 77.25 million. The consensus estimates are loss of $ 2.92 per share from $ 72.15 million in revenue. The bottom line results beat street analysts by $ 1 or 34.25 percent, at the same time, top line results outshined analysts by $ 5.10 million or 7.07 percent.
Stock Performance
On Friday, shares of Intercept Pharmaceuticals, Inc. has traded high as $ 29.55 and has cracked $ 27.72 on the downward trend, reaching $ 28.15 with volume of 603.70 thousand shares.
According to the previous trading day, closing price of $ 28.15, representing a 8.88 % increase from the 52 week low of $ 27.02 and a 76.46 % decrease over the 52 week high of $ 125.00.
The company has a market capital of $ 928.41 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Intercept Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.interceptpharma.com
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development.
